Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMNXJ5B)

Drug Name
TGFK08AA Drug Info
Indication
Disease Entry ICD 11 Status REF
Generalized anxiety disorder 6B00 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMNXJ5B

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
5-HT 1A receptor (HTR1A) DTT HTR1A 4.661 5.289 3.053 3.472
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Generalized anxiety disorder
ICD Disease Classification 6B00
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
5-HT 1A receptor (HTR1A) DTT HTR1A 2.18E-01 -0.11 -0.51
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
2 50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov. 2013 Sep;12(9):667-87.